| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| rho-Associated Kinases | 72 | 2021 | 161 | 12.010 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 66 | 2025 | 394 | 9.430 |
Why?
|
| Endothelium, Vascular | 71 | 2020 | 436 | 7.850 |
Why?
|
| Cardiovascular Diseases | 25 | 2022 | 755 | 3.490 |
Why?
|
| Stroke | 30 | 2019 | 1079 | 3.310 |
Why?
|
| Nitric Oxide Synthase Type III | 39 | 2020 | 83 | 2.790 |
Why?
|
| Brain Ischemia | 15 | 2020 | 414 | 2.700 |
Why?
|
| Nitric Oxide | 33 | 2018 | 281 | 2.670 |
Why?
|
| Nitric Oxide Synthase | 30 | 2005 | 123 | 2.500 |
Why?
|
| Cardiomegaly | 12 | 2016 | 111 | 2.430 |
Why?
|
| Leukocytes | 18 | 2016 | 210 | 2.190 |
Why?
|
| Neovascularization, Physiologic | 12 | 2024 | 140 | 1.900 |
Why?
|
| Animals | 146 | 2025 | 28041 | 1.850 |
Why?
|
| Muscle, Smooth, Vascular | 16 | 2014 | 232 | 1.840 |
Why?
|
| Cholesterol | 21 | 2022 | 364 | 1.770 |
Why?
|
| Signal Transduction | 41 | 2025 | 3498 | 1.760 |
Why?
|
| Simvastatin | 17 | 2019 | 106 | 1.690 |
Why?
|
| Atherosclerosis | 17 | 2017 | 256 | 1.660 |
Why?
|
| Protein Kinase Inhibitors | 14 | 2020 | 603 | 1.620 |
Why?
|
| Phosphatidylinositol 3-Kinases | 11 | 2006 | 281 | 1.610 |
Why?
|
| Cardiovascular System | 6 | 2017 | 52 | 1.510 |
Why?
|
| Endothelial Cells | 18 | 2025 | 477 | 1.500 |
Why?
|
| Mice | 84 | 2025 | 12233 | 1.470 |
Why?
|
| Dyslipidemias | 4 | 2022 | 108 | 1.460 |
Why?
|
| Cells, Cultured | 53 | 2024 | 2828 | 1.420 |
Why?
|
| Enzyme Inhibitors | 21 | 2019 | 639 | 1.370 |
Why?
|
| Receptor, Notch1 | 7 | 2011 | 101 | 1.360 |
Why?
|
| Proto-Oncogene Proteins c-akt | 16 | 2020 | 364 | 1.300 |
Why?
|
| rac1 GTP-Binding Protein | 10 | 2013 | 47 | 1.260 |
Why?
|
| Mice, Knockout | 37 | 2025 | 2121 | 1.190 |
Why?
|
| Myocytes, Cardiac | 10 | 2024 | 313 | 1.190 |
Why?
|
| Disease Models, Animal | 24 | 2024 | 2491 | 1.130 |
Why?
|
| Anticholesteremic Agents | 6 | 2011 | 154 | 1.130 |
Why?
|
| Humans | 163 | 2025 | 93615 | 1.110 |
Why?
|
| Coronary Artery Disease | 9 | 2019 | 375 | 1.060 |
Why?
|
| Hypercholesterolemia | 7 | 2010 | 160 | 1.050 |
Why?
|
| Transcription Factors | 9 | 2012 | 1690 | 1.040 |
Why?
|
| Carotid Arteries | 5 | 2020 | 131 | 1.010 |
Why?
|
| Enzyme Activation | 23 | 2015 | 672 | 1.000 |
Why?
|
| Vascular Stiffness | 4 | 2021 | 28 | 0.990 |
Why?
|
| Neovascularization, Pathologic | 6 | 2016 | 353 | 0.980 |
Why?
|
| Anti-Inflammatory Agents | 5 | 2022 | 353 | 0.980 |
Why?
|
| Hemorrhage | 4 | 2017 | 289 | 0.970 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 14 | 2019 | 392 | 0.940 |
Why?
|
| Transcription, Genetic | 14 | 2006 | 1115 | 0.930 |
Why?
|
| Myocardial Infarction | 7 | 2025 | 385 | 0.920 |
Why?
|
| Cattle | 26 | 2011 | 394 | 0.910 |
Why?
|
| Genetic Pleiotropy | 2 | 2017 | 29 | 0.910 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 11 | 2019 | 36 | 0.900 |
Why?
|
| Cholesterol, LDL | 9 | 2023 | 246 | 0.890 |
Why?
|
| Mice, Inbred C57BL | 33 | 2025 | 3430 | 0.890 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 304 | 0.880 |
Why?
|
| Ischemia | 10 | 2011 | 253 | 0.880 |
Why?
|
| NF-kappa B | 15 | 2010 | 408 | 0.850 |
Why?
|
| Antioxidants | 8 | 2005 | 231 | 0.830 |
Why?
|
| Tumor Necrosis Factor-alpha | 10 | 2017 | 688 | 0.820 |
Why?
|
| rho GTP-Binding Proteins | 8 | 2013 | 57 | 0.820 |
Why?
|
| Proto-Oncogene Proteins | 8 | 2012 | 665 | 0.790 |
Why?
|
| Vascular Diseases | 5 | 2016 | 118 | 0.780 |
Why?
|
| Heart Failure | 8 | 2024 | 1388 | 0.780 |
Why?
|
| GTP-Binding Proteins | 9 | 2008 | 147 | 0.740 |
Why?
|
| Heptanoic Acids | 6 | 2013 | 72 | 0.730 |
Why?
|
| Male | 79 | 2025 | 44578 | 0.700 |
Why?
|
| Pyrroles | 6 | 2013 | 165 | 0.690 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 10 | 2013 | 58 | 0.690 |
Why?
|
| Angiotensin II | 8 | 2014 | 94 | 0.690 |
Why?
|
| Receptors, Estrogen | 5 | 2003 | 413 | 0.670 |
Why?
|
| Ventricular Remodeling | 2 | 2024 | 99 | 0.670 |
Why?
|
| Inflammation | 7 | 2016 | 1049 | 0.660 |
Why?
|
| rhoA GTP-Binding Protein | 10 | 2019 | 87 | 0.660 |
Why?
|
| Thrombosis | 2 | 2023 | 309 | 0.660 |
Why?
|
| Up-Regulation | 13 | 2018 | 729 | 0.660 |
Why?
|
| Estrogens | 6 | 2003 | 195 | 0.650 |
Why?
|
| Biomarkers | 12 | 2022 | 1912 | 0.650 |
Why?
|
| RGS Proteins | 1 | 2020 | 19 | 0.650 |
Why?
|
| Dipyridamole | 3 | 2008 | 12 | 0.610 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 5 | 2025 | 259 | 0.610 |
Why?
|
| Gene Expression Regulation, Enzymologic | 9 | 2015 | 215 | 0.610 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 3 | 2009 | 63 | 0.590 |
Why?
|
| Muscle Proteins | 2 | 2012 | 129 | 0.590 |
Why?
|
| 8,11,14-Eicosatrienoic Acid | 5 | 2004 | 11 | 0.590 |
Why?
|
| Vascular Endothelial Growth Factor A | 10 | 2024 | 398 | 0.580 |
Why?
|
| Aorta | 17 | 2014 | 273 | 0.570 |
Why?
|
| Tunica Intima | 2 | 2009 | 61 | 0.560 |
Why?
|
| RNA, Messenger | 24 | 2015 | 2020 | 0.560 |
Why?
|
| Cell Movement | 11 | 2015 | 804 | 0.550 |
Why?
|
| Phosphorylation | 15 | 2018 | 1130 | 0.550 |
Why?
|
| Neuroprotection | 1 | 2018 | 6 | 0.540 |
Why?
|
| Cellular Senescence | 2 | 2009 | 106 | 0.540 |
Why?
|
| rac GTP-Binding Proteins | 4 | 2013 | 24 | 0.540 |
Why?
|
| Coronary Angiography | 3 | 2016 | 232 | 0.530 |
Why?
|
| Cyclic GMP | 3 | 2024 | 62 | 0.510 |
Why?
|
| Hindlimb | 5 | 2011 | 94 | 0.510 |
Why?
|
| Cerebrovascular Circulation | 9 | 2008 | 239 | 0.510 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 3 | 2006 | 46 | 0.510 |
Why?
|
| Drug Design | 3 | 2015 | 133 | 0.500 |
Why?
|
| Cell Cycle Proteins | 3 | 2008 | 409 | 0.500 |
Why?
|
| Hypertension | 7 | 2019 | 758 | 0.500 |
Why?
|
| Cardiomyopathy, Dilated | 3 | 2007 | 85 | 0.490 |
Why?
|
| Polyisoprenyl Phosphates | 5 | 2006 | 5 | 0.490 |
Why?
|
| Angiopoietin-2 | 1 | 2016 | 21 | 0.480 |
Why?
|
| Vasodilation | 11 | 2019 | 91 | 0.480 |
Why?
|
| Estradiol | 3 | 2024 | 247 | 0.480 |
Why?
|
| Angina Pectoris | 2 | 2015 | 20 | 0.470 |
Why?
|
| Troponin T | 1 | 2016 | 42 | 0.460 |
Why?
|
| Acute Coronary Syndrome | 3 | 2015 | 33 | 0.460 |
Why?
|
| Oxidative Stress | 9 | 2013 | 467 | 0.460 |
Why?
|
| Down-Regulation | 6 | 2008 | 523 | 0.450 |
Why?
|
| Bronchial Hyperreactivity | 2 | 2015 | 73 | 0.450 |
Why?
|
| LIM-Homeodomain Proteins | 2 | 2012 | 21 | 0.450 |
Why?
|
| Bone Marrow Cells | 3 | 2011 | 264 | 0.440 |
Why?
|
| Neuropeptides | 3 | 2013 | 114 | 0.440 |
Why?
|
| Myocardium | 5 | 2025 | 570 | 0.440 |
Why?
|
| Gene Expression Regulation | 12 | 2013 | 1980 | 0.440 |
Why?
|
| Apoptosis | 12 | 2018 | 1719 | 0.440 |
Why?
|
| Arteriosclerosis | 6 | 2004 | 106 | 0.430 |
Why?
|
| Nerve Tissue Proteins | 4 | 2011 | 501 | 0.430 |
Why?
|
| Coronary Disease | 4 | 2007 | 223 | 0.430 |
Why?
|
| Hypolipidemic Agents | 3 | 2023 | 96 | 0.420 |
Why?
|
| Oxygenases | 4 | 2004 | 17 | 0.420 |
Why?
|
| Hypersensitivity | 2 | 2017 | 162 | 0.410 |
Why?
|
| Fibrosis | 5 | 2020 | 230 | 0.410 |
Why?
|
| Cytochrome P-450 Enzyme System | 4 | 2004 | 77 | 0.410 |
Why?
|
| GTP Phosphohydrolases | 7 | 2015 | 80 | 0.410 |
Why?
|
| Mice, Transgenic | 11 | 2020 | 1584 | 0.410 |
Why?
|
| Superoxides | 5 | 2007 | 75 | 0.410 |
Why?
|
| NADPH Oxidases | 5 | 2007 | 85 | 0.410 |
Why?
|
| Blotting, Western | 13 | 2012 | 775 | 0.400 |
Why?
|
| Atrial Fibrillation | 1 | 2019 | 419 | 0.400 |
Why?
|
| Rats | 16 | 2010 | 4042 | 0.400 |
Why?
|
| Obesity | 2 | 2012 | 1019 | 0.400 |
Why?
|
| Female | 48 | 2025 | 48779 | 0.390 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2014 | 75 | 0.390 |
Why?
|
| Blood-Brain Barrier | 3 | 2021 | 80 | 0.390 |
Why?
|
| Blood Pressure | 9 | 2019 | 896 | 0.390 |
Why?
|
| Genes, MHC Class II | 2 | 2004 | 28 | 0.390 |
Why?
|
| Treatment Outcome | 14 | 2025 | 9108 | 0.380 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2012 | 214 | 0.380 |
Why?
|
| Reperfusion Injury | 2 | 2012 | 148 | 0.380 |
Why?
|
| Dose-Response Relationship, Drug | 16 | 2015 | 1913 | 0.380 |
Why?
|
| Cyclic AMP | 4 | 2008 | 276 | 0.370 |
Why?
|
| I-kappa B Proteins | 5 | 2000 | 47 | 0.370 |
Why?
|
| Reactive Oxygen Species | 3 | 2011 | 502 | 0.370 |
Why?
|
| Ischemic Attack, Transient | 3 | 2007 | 184 | 0.360 |
Why?
|
| Heart-Assist Devices | 2 | 2017 | 882 | 0.360 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2015 | 210 | 0.360 |
Why?
|
| Coronary Vasospasm | 1 | 2012 | 7 | 0.360 |
Why?
|
| Middle Aged | 35 | 2025 | 27621 | 0.360 |
Why?
|
| Lung | 2 | 2018 | 1365 | 0.360 |
Why?
|
| Preoperative Care | 1 | 2014 | 407 | 0.350 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2012 | 297 | 0.350 |
Why?
|
| Regional Blood Flow | 7 | 2008 | 186 | 0.350 |
Why?
|
| Nitric Oxide Synthase Type II | 13 | 2006 | 89 | 0.350 |
Why?
|
| Cell Adhesion | 11 | 2016 | 416 | 0.350 |
Why?
|
| Repressor Proteins | 4 | 2009 | 443 | 0.350 |
Why?
|
| Mitochondria, Muscle | 1 | 2011 | 25 | 0.350 |
Why?
|
| Insulin Resistance | 2 | 2012 | 379 | 0.350 |
Why?
|
| Aged | 27 | 2025 | 20469 | 0.350 |
Why?
|
| Oxazepines | 1 | 2011 | 5 | 0.340 |
Why?
|
| Farnesyl-Diphosphate Farnesyltransferase | 1 | 2011 | 5 | 0.340 |
Why?
|
| Risk Factors | 12 | 2023 | 5912 | 0.340 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 4 | 2009 | 179 | 0.340 |
Why?
|
| Vasculitis | 2 | 2008 | 40 | 0.330 |
Why?
|
| Tissue Plasminogen Activator | 3 | 2005 | 180 | 0.330 |
Why?
|
| Diet, High-Fat | 1 | 2012 | 135 | 0.330 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 5 | 2024 | 70 | 0.330 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2011 | 59 | 0.330 |
Why?
|
| MAP Kinase Kinase Kinase 5 | 2 | 2007 | 3 | 0.320 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 2 | 2002 | 17 | 0.320 |
Why?
|
| Isoenzymes | 3 | 2020 | 271 | 0.320 |
Why?
|
| Protein Isoforms | 4 | 2021 | 295 | 0.320 |
Why?
|
| Muscle, Skeletal | 2 | 2011 | 474 | 0.310 |
Why?
|
| Piperidines | 1 | 2011 | 165 | 0.310 |
Why?
|
| Cell Line | 11 | 2020 | 2459 | 0.310 |
Why?
|
| Lipoproteins, LDL | 7 | 2012 | 83 | 0.310 |
Why?
|
| Blood Vessels | 2 | 2009 | 91 | 0.300 |
Why?
|
| Regeneration | 1 | 2010 | 159 | 0.300 |
Why?
|
| Cell Proliferation | 7 | 2014 | 1735 | 0.300 |
Why?
|
| Pyrimidines | 2 | 2008 | 384 | 0.300 |
Why?
|
| Cerebral Hemorrhage | 2 | 2025 | 367 | 0.300 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2013 | 304 | 0.290 |
Why?
|
| Genome, Human | 1 | 2014 | 823 | 0.290 |
Why?
|
| Hemangioma, Cavernous | 2 | 2019 | 66 | 0.290 |
Why?
|
| Nerve Growth Factors | 1 | 2009 | 53 | 0.290 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2000 | 185 | 0.290 |
Why?
|
| Promoter Regions, Genetic | 10 | 2004 | 959 | 0.290 |
Why?
|
| Lovastatin | 5 | 2001 | 28 | 0.290 |
Why?
|
| Vasodilator Agents | 9 | 2019 | 133 | 0.290 |
Why?
|
| Fluorobenzenes | 1 | 2008 | 34 | 0.290 |
Why?
|
| Estrogen Receptor alpha | 3 | 2024 | 155 | 0.280 |
Why?
|
| Azetidines | 1 | 2008 | 36 | 0.280 |
Why?
|
| Myocytes, Smooth Muscle | 5 | 2014 | 133 | 0.280 |
Why?
|
| Hyperlipidemias | 1 | 2008 | 91 | 0.280 |
Why?
|
| RNA Stability | 5 | 2008 | 97 | 0.270 |
Why?
|
| Oxidation-Reduction | 6 | 2008 | 410 | 0.270 |
Why?
|
| Endothelium | 2 | 2009 | 59 | 0.270 |
Why?
|
| Drug Therapy, Combination | 3 | 2022 | 759 | 0.270 |
Why?
|
| Actinin | 1 | 2008 | 19 | 0.270 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2008 | 30 | 0.270 |
Why?
|
| Nuclear Proteins | 2 | 2011 | 740 | 0.270 |
Why?
|
| Heart | 3 | 2012 | 522 | 0.270 |
Why?
|
| Calmodulin | 1 | 2008 | 50 | 0.270 |
Why?
|
| Genetic Variation | 1 | 2014 | 1415 | 0.260 |
Why?
|
| Brain | 7 | 2021 | 2375 | 0.260 |
Why?
|
| Hyperaldosteronism | 2 | 2019 | 13 | 0.260 |
Why?
|
| Clinical Trials as Topic | 6 | 2017 | 1103 | 0.260 |
Why?
|
| Receptors, Bradykinin | 3 | 1997 | 11 | 0.260 |
Why?
|
| Protein Prenylation | 6 | 2005 | 10 | 0.260 |
Why?
|
| Stem Cells | 2 | 2011 | 386 | 0.260 |
Why?
|
| Cell Adhesion Molecules | 5 | 2001 | 174 | 0.250 |
Why?
|
| Immunity, Innate | 1 | 2010 | 463 | 0.250 |
Why?
|
| Insulin | 1 | 2012 | 1185 | 0.250 |
Why?
|
| Cerebral Infarction | 4 | 2018 | 73 | 0.250 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2003 | 289 | 0.240 |
Why?
|
| Sulfonamides | 1 | 2008 | 331 | 0.240 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 4 | 2003 | 249 | 0.240 |
Why?
|
| Microfilament Proteins | 1 | 2008 | 209 | 0.240 |
Why?
|
| Time Factors | 13 | 2019 | 5406 | 0.240 |
Why?
|
| Postoperative Complications | 2 | 2017 | 2564 | 0.240 |
Why?
|
| Circadian Rhythm | 1 | 2008 | 285 | 0.240 |
Why?
|
| Mice, Mutant Strains | 5 | 2015 | 219 | 0.240 |
Why?
|
| Emergency Service, Hospital | 3 | 2021 | 582 | 0.240 |
Why?
|
| Saphenous Vein | 6 | 2006 | 59 | 0.240 |
Why?
|
| Metalloporphyrins | 2 | 2016 | 26 | 0.240 |
Why?
|
| Receptors, Thyroid Hormone | 1 | 2006 | 158 | 0.230 |
Why?
|
| Metabolic Syndrome | 1 | 2007 | 122 | 0.230 |
Why?
|
| Carrier Proteins | 1 | 2009 | 660 | 0.230 |
Why?
|
| Hydrogen Peroxide | 3 | 2007 | 164 | 0.230 |
Why?
|
| Cholesterol, HDL | 3 | 2016 | 173 | 0.230 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2006 | 91 | 0.230 |
Why?
|
| Animals, Newborn | 1 | 2006 | 519 | 0.230 |
Why?
|
| NG-Nitroarginine Methyl Ester | 6 | 2008 | 45 | 0.230 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2007 | 179 | 0.220 |
Why?
|
| Aryl Hydrocarbon Receptor Nuclear Translocator | 1 | 2025 | 14 | 0.220 |
Why?
|
| Cell Survival | 5 | 2013 | 1003 | 0.220 |
Why?
|
| Thrombin | 3 | 2017 | 60 | 0.220 |
Why?
|
| Infarction, Middle Cerebral Artery | 4 | 2018 | 54 | 0.220 |
Why?
|
| Terpenes | 3 | 2010 | 18 | 0.220 |
Why?
|
| Rifabutin | 1 | 2004 | 3 | 0.220 |
Why?
|
| Patient Readmission | 2 | 2020 | 412 | 0.220 |
Why?
|
| Ovariectomy | 1 | 2024 | 91 | 0.210 |
Why?
|
| Carotid Stenosis | 1 | 2005 | 114 | 0.210 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2004 | 45 | 0.210 |
Why?
|
| Ventricular Function, Left | 2 | 2024 | 520 | 0.210 |
Why?
|
| Peptide Elongation Factor 1 | 2 | 2018 | 10 | 0.210 |
Why?
|
| Predictive Value of Tests | 6 | 2014 | 1715 | 0.210 |
Why?
|
| Hyperglycemia | 1 | 2005 | 181 | 0.210 |
Why?
|
| Thyroid Hormones | 1 | 2006 | 350 | 0.200 |
Why?
|
| Coculture Techniques | 4 | 2024 | 170 | 0.200 |
Why?
|
| Receptors, Cell Surface | 1 | 2005 | 292 | 0.200 |
Why?
|
| Cell Division | 5 | 2003 | 690 | 0.200 |
Why?
|
| Heart Function Tests | 1 | 2003 | 28 | 0.200 |
Why?
|
| Eicosanoids | 2 | 2004 | 17 | 0.200 |
Why?
|
| Inflammation Mediators | 3 | 2015 | 159 | 0.200 |
Why?
|
| Mutation | 4 | 2012 | 4266 | 0.200 |
Why?
|
| Dexamethasone | 2 | 2002 | 311 | 0.200 |
Why?
|
| Structure-Activity Relationship | 3 | 2015 | 423 | 0.190 |
Why?
|
| Neuroprotective Agents | 6 | 2010 | 98 | 0.190 |
Why?
|
| Antihypertensive Agents | 3 | 2019 | 262 | 0.190 |
Why?
|
| Transfection | 6 | 2013 | 878 | 0.190 |
Why?
|
| Naphthalenes | 1 | 2003 | 40 | 0.190 |
Why?
|
| Risk Assessment | 5 | 2019 | 2444 | 0.190 |
Why?
|
| Cell Cycle | 2 | 2001 | 515 | 0.190 |
Why?
|
| Homeodomain Proteins | 1 | 2006 | 556 | 0.190 |
Why?
|
| Anions | 1 | 2002 | 30 | 0.190 |
Why?
|
| C-Reactive Protein | 4 | 2016 | 204 | 0.190 |
Why?
|
| Ergosterol | 1 | 2002 | 3 | 0.190 |
Why?
|
| Porins | 1 | 2002 | 24 | 0.190 |
Why?
|
| Receptors, Glucocorticoid | 2 | 2003 | 144 | 0.180 |
Why?
|
| Interferon-gamma | 2 | 2002 | 460 | 0.180 |
Why?
|
| Raloxifene Hydrochloride | 1 | 2002 | 10 | 0.180 |
Why?
|
| Membrane Proteins | 3 | 2007 | 1260 | 0.180 |
Why?
|
| Case-Control Studies | 6 | 2017 | 1933 | 0.180 |
Why?
|
| S-Nitrosoglutathione | 5 | 2003 | 10 | 0.180 |
Why?
|
| Nitroso Compounds | 5 | 2003 | 12 | 0.180 |
Why?
|
| Cytoplasm | 1 | 2002 | 277 | 0.180 |
Why?
|
| Umbilical Veins | 3 | 2006 | 45 | 0.180 |
Why?
|
| Pneumonia | 2 | 2015 | 193 | 0.170 |
Why?
|
| Salicylates | 1 | 2001 | 25 | 0.170 |
Why?
|
| Mevalonic Acid | 5 | 2006 | 12 | 0.170 |
Why?
|
| Cardiotonic Agents | 1 | 2002 | 88 | 0.170 |
Why?
|
| Calcitriol | 1 | 2002 | 173 | 0.170 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2021 | 10 | 0.170 |
Why?
|
| Prospective Studies | 6 | 2019 | 4565 | 0.170 |
Why?
|
| Bone Marrow Transplantation | 4 | 2012 | 281 | 0.170 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2001 | 19 | 0.170 |
Why?
|
| Sodium Salicylate | 1 | 2000 | 4 | 0.170 |
Why?
|
| Gene Expression | 4 | 2011 | 1302 | 0.170 |
Why?
|
| Double-Blind Method | 6 | 2025 | 1731 | 0.160 |
Why?
|
| Amides | 3 | 2011 | 54 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2007 | 920 | 0.160 |
Why?
|
| Cyclins | 1 | 2000 | 80 | 0.160 |
Why?
|
| Muscle Contraction | 5 | 2015 | 256 | 0.160 |
Why?
|
| Follow-Up Studies | 9 | 2019 | 3835 | 0.160 |
Why?
|
| Receptors, AMPA | 1 | 2020 | 68 | 0.160 |
Why?
|
| Office Visits | 1 | 2020 | 47 | 0.160 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2013 | 122 | 0.160 |
Why?
|
| MAP Kinase Signaling System | 1 | 2021 | 200 | 0.160 |
Why?
|
| Nitroprusside | 4 | 2014 | 25 | 0.160 |
Why?
|
| Blotting, Northern | 5 | 2007 | 239 | 0.160 |
Why?
|
| Community Health Workers | 1 | 2020 | 37 | 0.160 |
Why?
|
| Brachial Artery | 5 | 2019 | 37 | 0.160 |
Why?
|
| Severity of Illness Index | 4 | 2013 | 1918 | 0.160 |
Why?
|
| Interferon Regulatory Factors | 3 | 2020 | 75 | 0.160 |
Why?
|
| Germinal Center | 1 | 2020 | 62 | 0.160 |
Why?
|
| Taiwan | 2 | 2012 | 25 | 0.150 |
Why?
|
| Pyridines | 4 | 2011 | 302 | 0.150 |
Why?
|
| DNA-Binding Proteins | 5 | 2001 | 1233 | 0.150 |
Why?
|
| Cell Communication | 1 | 2001 | 216 | 0.150 |
Why?
|
| Prognosis | 8 | 2015 | 3913 | 0.150 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 56 | 0.150 |
Why?
|
| Receptors, Notch | 3 | 2009 | 138 | 0.150 |
Why?
|
| Drug Delivery Systems | 3 | 2011 | 193 | 0.150 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2014 | 2484 | 0.150 |
Why?
|
| Gene Deletion | 3 | 2017 | 351 | 0.150 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2007 | 1243 | 0.150 |
Why?
|
| Fibroblasts | 2 | 2018 | 752 | 0.150 |
Why?
|
| Sirolimus | 2 | 2012 | 176 | 0.150 |
Why?
|
| Urban Population | 1 | 2020 | 234 | 0.150 |
Why?
|
| Rats, Wistar | 4 | 2004 | 300 | 0.140 |
Why?
|
| Goblet Cells | 3 | 2017 | 20 | 0.140 |
Why?
|
| Immunologic Factors | 2 | 2012 | 176 | 0.140 |
Why?
|
| Disease Susceptibility | 3 | 2009 | 221 | 0.140 |
Why?
|
| Botulinum Toxins | 1 | 1998 | 16 | 0.140 |
Why?
|
| Precipitin Tests | 3 | 2003 | 101 | 0.140 |
Why?
|
| Myosin-Light-Chain Phosphatase | 4 | 2013 | 9 | 0.140 |
Why?
|
| Macrophages | 3 | 2012 | 610 | 0.140 |
Why?
|
| Bronchoalveolar Lavage Fluid | 3 | 2017 | 133 | 0.140 |
Why?
|
| Pre-Eclampsia | 1 | 2021 | 261 | 0.140 |
Why?
|
| Mitochondria | 2 | 2016 | 612 | 0.140 |
Why?
|
| Social Determinants of Health | 1 | 2019 | 108 | 0.140 |
Why?
|
| Models, Biological | 4 | 2012 | 1768 | 0.140 |
Why?
|
| In Vitro Techniques | 5 | 2010 | 947 | 0.140 |
Why?
|
| Aspirin | 3 | 2007 | 167 | 0.140 |
Why?
|
| Violence | 1 | 2019 | 152 | 0.130 |
Why?
|
| Intracranial Hemorrhages | 1 | 2019 | 135 | 0.130 |
Why?
|
| Arginine | 3 | 2008 | 140 | 0.130 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2008 | 98 | 0.130 |
Why?
|
| Adult | 16 | 2025 | 27955 | 0.130 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 1997 | 18 | 0.130 |
Why?
|
| Hypoxia | 2 | 2005 | 675 | 0.130 |
Why?
|
| Protein Binding | 5 | 2012 | 1528 | 0.130 |
Why?
|
| Vascular Remodeling | 1 | 2017 | 21 | 0.130 |
Why?
|
| Amyloid Precursor Protein Secretases | 2 | 2009 | 98 | 0.130 |
Why?
|
| Coronary Vessels | 3 | 2013 | 178 | 0.130 |
Why?
|
| Escherichia coli Proteins | 1 | 1998 | 179 | 0.130 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 1998 | 123 | 0.130 |
Why?
|
| Nitric Oxide Donors | 2 | 2015 | 13 | 0.130 |
Why?
|
| Blood Platelets | 3 | 2017 | 150 | 0.130 |
Why?
|
| Glutathione | 4 | 1997 | 105 | 0.130 |
Why?
|
| Caspase 3 | 3 | 2006 | 161 | 0.120 |
Why?
|
| Caspases | 3 | 2006 | 151 | 0.120 |
Why?
|
| T-Lymphocytes | 3 | 2012 | 1275 | 0.120 |
Why?
|
| Ethanol | 1 | 1999 | 273 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2011 | 885 | 0.120 |
Why?
|
| Peptide Fragments | 3 | 2012 | 469 | 0.120 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2013 | 408 | 0.120 |
Why?
|
| Pandemics | 1 | 2022 | 875 | 0.120 |
Why?
|
| Fractals | 1 | 2016 | 41 | 0.120 |
Why?
|
| Pulmonary Fibrosis | 1 | 2018 | 152 | 0.120 |
Why?
|
| Kinetics | 4 | 2000 | 1470 | 0.120 |
Why?
|
| Triglycerides | 2 | 2008 | 231 | 0.120 |
Why?
|
| Cardiology | 1 | 2017 | 120 | 0.120 |
Why?
|
| Binding Sites | 5 | 2006 | 1128 | 0.120 |
Why?
|
| Arteriovenous Malformations | 1 | 2016 | 49 | 0.120 |
Why?
|
| Oxidants, Photochemical | 1 | 2015 | 1 | 0.120 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 701 | 0.120 |
Why?
|
| Ozone | 1 | 2015 | 12 | 0.120 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2012 | 59 | 0.110 |
Why?
|
| Intercellular Adhesion Molecule-1 | 3 | 2008 | 76 | 0.110 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2015 | 11 | 0.110 |
Why?
|
| Analysis of Variance | 2 | 2009 | 884 | 0.110 |
Why?
|
| Isosorbide Dinitrate | 1 | 2015 | 2 | 0.110 |
Why?
|
| Aged, 80 and over | 7 | 2025 | 7073 | 0.110 |
Why?
|
| Transforming Growth Factor beta | 1 | 1997 | 347 | 0.110 |
Why?
|
| Heart Diseases | 2 | 2010 | 257 | 0.110 |
Why?
|
| Lipid Metabolism | 2 | 2009 | 214 | 0.110 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2015 | 36 | 0.110 |
Why?
|
| Capillary Permeability | 2 | 2018 | 131 | 0.110 |
Why?
|
| Reference Values | 2 | 2007 | 608 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2012 | 216 | 0.110 |
Why?
|
| Cytokines | 2 | 2015 | 863 | 0.110 |
Why?
|
| Cyclic GMP-Dependent Protein Kinases | 2 | 2024 | 17 | 0.100 |
Why?
|
| Quinolines | 2 | 2013 | 85 | 0.100 |
Why?
|
| Molecular Sequence Data | 6 | 2014 | 2889 | 0.100 |
Why?
|
| Calcium Channel Blockers | 2 | 2011 | 118 | 0.100 |
Why?
|
| Interleukin-17 | 2 | 2015 | 109 | 0.100 |
Why?
|
| Proteins | 1 | 1999 | 800 | 0.100 |
Why?
|
| Prenylation | 1 | 2013 | 3 | 0.100 |
Why?
|
| Platelet Aggregation | 2 | 2017 | 40 | 0.100 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 381 | 0.100 |
Why?
|
| Phenylephrine | 2 | 2006 | 33 | 0.100 |
Why?
|
| Vitamin D | 1 | 2016 | 272 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2017 | 481 | 0.100 |
Why?
|
| DNA | 4 | 2006 | 1260 | 0.100 |
Why?
|
| Cognition | 1 | 2018 | 627 | 0.100 |
Why?
|
| Receptor, TIE-2 | 2 | 2015 | 18 | 0.100 |
Why?
|
| Blood Flow Velocity | 3 | 2010 | 179 | 0.100 |
Why?
|
| Arginase | 1 | 2013 | 15 | 0.100 |
Why?
|
| Recombinant Proteins | 4 | 2021 | 982 | 0.100 |
Why?
|
| Cytosol | 2 | 2007 | 192 | 0.100 |
Why?
|
| Smoking | 2 | 2010 | 648 | 0.100 |
Why?
|
| Diabetic Angiopathies | 1 | 2013 | 37 | 0.100 |
Why?
|
| Nitroglycerin | 4 | 2019 | 24 | 0.100 |
Why?
|
| Hemangiosarcoma | 1 | 2013 | 16 | 0.100 |
Why?
|
| Sphingosine | 2 | 2010 | 73 | 0.100 |
Why?
|
| Protein Structure, Tertiary | 2 | 2006 | 726 | 0.100 |
Why?
|
| Plakophilins | 1 | 2012 | 4 | 0.100 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 1866 | 0.100 |
Why?
|
| Mesothelioma | 1 | 2016 | 331 | 0.100 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2013 | 75 | 0.090 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2013 | 56 | 0.090 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 990 | 0.090 |
Why?
|
| Femoral Artery | 2 | 2004 | 90 | 0.090 |
Why?
|
| Penis | 1 | 2013 | 61 | 0.090 |
Why?
|
| Atrial Natriuretic Factor | 2 | 2003 | 38 | 0.090 |
Why?
|
| Arteries | 2 | 2011 | 171 | 0.090 |
Why?
|
| Stroke Volume | 4 | 2012 | 440 | 0.090 |
Why?
|
| Interleukin-1 | 3 | 2006 | 71 | 0.090 |
Why?
|
| Adenoma | 1 | 2015 | 258 | 0.090 |
Why?
|
| Survival Rate | 2 | 2008 | 1950 | 0.090 |
Why?
|
| Receptor, Notch3 | 2 | 2009 | 4 | 0.090 |
Why?
|
| Adherens Junctions | 1 | 2012 | 34 | 0.090 |
Why?
|
| Receptors, Adrenergic, alpha | 1 | 1992 | 15 | 0.090 |
Why?
|
| Receptors, Neurotransmitter | 1 | 1992 | 24 | 0.090 |
Why?
|
| RNA, Small Interfering | 3 | 2013 | 555 | 0.090 |
Why?
|
| Bradykinin | 1 | 1992 | 44 | 0.090 |
Why?
|
| Cell Differentiation | 4 | 2018 | 1610 | 0.090 |
Why?
|
| Citrulline | 1 | 2012 | 10 | 0.090 |
Why?
|
| Mice, Inbred C3H | 1 | 2012 | 369 | 0.090 |
Why?
|
| Protein Conformation | 1 | 2015 | 910 | 0.090 |
Why?
|
| Oncogene Protein v-akt | 1 | 2012 | 21 | 0.090 |
Why?
|
| Spironolactone | 1 | 2011 | 12 | 0.090 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2011 | 20 | 0.090 |
Why?
|
| Proadifen | 2 | 2002 | 2 | 0.090 |
Why?
|
| Ergonovine | 1 | 1991 | 2 | 0.090 |
Why?
|
| Uterine Hemorrhage | 1 | 1991 | 21 | 0.090 |
Why?
|
| Actins | 3 | 2005 | 467 | 0.090 |
Why?
|
| Apolipoproteins E | 3 | 2010 | 136 | 0.090 |
Why?
|
| Mesenteric Arteries | 1 | 2011 | 29 | 0.090 |
Why?
|
| Interleukin-5 | 1 | 2011 | 36 | 0.090 |
Why?
|
| Neurites | 1 | 2011 | 36 | 0.080 |
Why?
|
| Transcriptional Activation | 2 | 2010 | 290 | 0.080 |
Why?
|
| Huntington Disease | 1 | 2011 | 34 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 356 | 0.080 |
Why?
|
| Glucose | 2 | 2012 | 692 | 0.080 |
Why?
|
| Interleukin-13 | 1 | 2011 | 41 | 0.080 |
Why?
|
| Vascular Resistance | 1 | 1991 | 97 | 0.080 |
Why?
|
| Platelet-Derived Growth Factor | 2 | 2002 | 66 | 0.080 |
Why?
|
| Neuroimmunomodulation | 1 | 2010 | 13 | 0.080 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 812 | 0.080 |
Why?
|
| Aortic Diseases | 2 | 2012 | 87 | 0.080 |
Why?
|
| Abortion, Spontaneous | 1 | 1991 | 73 | 0.080 |
Why?
|
| Homocysteine | 1 | 2010 | 30 | 0.080 |
Why?
|
| Propylene Glycols | 1 | 2010 | 31 | 0.080 |
Why?
|
| Oxygen | 1 | 1995 | 769 | 0.080 |
Why?
|
| Corpus Striatum | 1 | 2011 | 83 | 0.080 |
Why?
|
| NF-KappaB Inhibitor alpha | 3 | 1999 | 38 | 0.080 |
Why?
|
| Eosinophils | 1 | 2011 | 194 | 0.080 |
Why?
|
| Respiratory Mechanics | 1 | 2011 | 108 | 0.080 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2010 | 12 | 0.080 |
Why?
|
| Muscle, Smooth | 2 | 2015 | 300 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2000 | 35 | 0.080 |
Why?
|
| Ultrasonography | 5 | 2019 | 702 | 0.080 |
Why?
|
| Cell Nucleus | 2 | 2002 | 602 | 0.080 |
Why?
|
| Carotid Artery Injuries | 1 | 2010 | 21 | 0.080 |
Why?
|
| Myosins | 1 | 2010 | 86 | 0.080 |
Why?
|
| Green Fluorescent Proteins | 1 | 2011 | 309 | 0.080 |
Why?
|
| Cyclin-Dependent Kinases | 2 | 2000 | 42 | 0.080 |
Why?
|
| Calcium | 2 | 2006 | 1175 | 0.080 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2008 | 47 | 0.080 |
Why?
|
| Interleukins | 1 | 2010 | 133 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2002 | 554 | 0.080 |
Why?
|
| Cadherins | 1 | 2011 | 180 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2013 | 713 | 0.080 |
Why?
|
| Immunoblotting | 3 | 2011 | 273 | 0.080 |
Why?
|
| COS Cells | 3 | 2008 | 163 | 0.080 |
Why?
|
| DNA, Complementary | 2 | 2003 | 379 | 0.070 |
Why?
|
| Drug Synergism | 2 | 2008 | 315 | 0.070 |
Why?
|
| Osteopontin | 2 | 2015 | 48 | 0.070 |
Why?
|
| KRIT1 Protein | 2 | 2019 | 62 | 0.070 |
Why?
|
| Annexin A5 | 1 | 2009 | 20 | 0.070 |
Why?
|
| Azepines | 1 | 2009 | 28 | 0.070 |
Why?
|
| Microarray Analysis | 1 | 2009 | 95 | 0.070 |
Why?
|
| Alanine | 1 | 2009 | 83 | 0.070 |
Why?
|
| Genotype | 4 | 2010 | 1866 | 0.070 |
Why?
|
| Rosuvastatin Calcium | 1 | 2008 | 31 | 0.070 |
Why?
|
| Pravastatin | 2 | 2013 | 17 | 0.070 |
Why?
|
| Period Circadian Proteins | 1 | 2008 | 13 | 0.070 |
Why?
|
| Ezetimibe | 1 | 2008 | 37 | 0.070 |
Why?
|
| Receptor, Bradykinin B2 | 1 | 2008 | 1 | 0.070 |
Why?
|
| Japan | 3 | 2015 | 299 | 0.070 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2006 | 121 | 0.070 |
Why?
|
| Tubulin | 1 | 2008 | 61 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2008 | 52 | 0.070 |
Why?
|
| Cationic Amino Acid Transporter 1 | 1 | 2008 | 1 | 0.070 |
Why?
|
| Cell Hypoxia | 2 | 2002 | 187 | 0.070 |
Why?
|
| Aminoquinolines | 1 | 2008 | 20 | 0.070 |
Why?
|
| Base Sequence | 5 | 2014 | 2209 | 0.070 |
Why?
|
| Tertiary Care Centers | 2 | 2021 | 129 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2009 | 306 | 0.070 |
Why?
|
| Wound Healing | 2 | 2012 | 373 | 0.070 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2019 | 201 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2008 | 78 | 0.070 |
Why?
|
| Guanosine Triphosphate | 2 | 1998 | 36 | 0.070 |
Why?
|
| Eating | 1 | 2009 | 162 | 0.070 |
Why?
|
| Chemotaxis | 1 | 2008 | 74 | 0.070 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2008 | 55 | 0.070 |
Why?
|
| ras Proteins | 2 | 1999 | 132 | 0.070 |
Why?
|
| Neurons | 3 | 2011 | 1575 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2013 | 589 | 0.070 |
Why?
|
| Ultraviolet Rays | 1 | 2008 | 192 | 0.070 |
Why?
|
| Monocytes | 3 | 2000 | 215 | 0.070 |
Why?
|
| Body Mass Index | 2 | 2011 | 812 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 1923 | 0.070 |
Why?
|
| Thioredoxin Reductase 1 | 1 | 2007 | 1 | 0.070 |
Why?
|
| Thioredoxin-Disulfide Reductase | 1 | 2007 | 2 | 0.070 |
Why?
|
| Thioredoxin Reductase 2 | 1 | 2007 | 2 | 0.070 |
Why?
|
| Laser-Doppler Flowmetry | 2 | 2006 | 19 | 0.070 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2007 | 7 | 0.070 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2007 | 10 | 0.070 |
Why?
|
| Radiation Injuries | 1 | 2008 | 158 | 0.070 |
Why?
|
| Thioredoxins | 1 | 2007 | 12 | 0.070 |
Why?
|
| Drug Implants | 1 | 2007 | 37 | 0.070 |
Why?
|
| Acetophenones | 1 | 2007 | 27 | 0.060 |
Why?
|
| Dicarboxylic Acids | 1 | 2007 | 24 | 0.060 |
Why?
|
| Models, Neurological | 1 | 2010 | 408 | 0.060 |
Why?
|
| Retrospective Studies | 7 | 2020 | 10186 | 0.060 |
Why?
|
| Cell Size | 1 | 2007 | 71 | 0.060 |
Why?
|
| Hemodynamics | 2 | 2008 | 714 | 0.060 |
Why?
|
| Pulmonary Artery | 2 | 2002 | 333 | 0.060 |
Why?
|
| Brain Chemistry | 1 | 2007 | 117 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2008 | 105 | 0.060 |
Why?
|
| Ticlopidine | 1 | 2007 | 26 | 0.060 |
Why?
|
| Tetrazoles | 1 | 2007 | 21 | 0.060 |
Why?
|
| Aldosterone | 2 | 2019 | 55 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2014 | 2465 | 0.060 |
Why?
|
| Chromones | 1 | 2006 | 31 | 0.060 |
Why?
|
| Lipopolysaccharides | 2 | 2006 | 300 | 0.060 |
Why?
|
| Dendritic Cells | 1 | 2011 | 536 | 0.060 |
Why?
|
| Morpholines | 1 | 2006 | 61 | 0.060 |
Why?
|
| Drug Interactions | 1 | 2007 | 239 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2007 | 181 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 767 | 0.060 |
Why?
|
| Ankle Brachial Index | 2 | 2019 | 27 | 0.060 |
Why?
|
| Gingiva | 1 | 2006 | 7 | 0.060 |
Why?
|
| Androstadienes | 1 | 2006 | 71 | 0.060 |
Why?
|
| Nuclear Receptor Coactivator 3 | 1 | 2006 | 5 | 0.060 |
Why?
|
| GATA4 Transcription Factor | 1 | 2006 | 19 | 0.060 |
Why?
|
| Superoxide Dismutase | 2 | 2016 | 155 | 0.060 |
Why?
|
| Socioeconomic Factors | 2 | 2020 | 629 | 0.060 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2022 | 41 | 0.060 |
Why?
|
| Endothelin-1 | 1 | 2006 | 41 | 0.060 |
Why?
|
| Interleukin-8 | 1 | 2006 | 88 | 0.060 |
Why?
|
| Chemokines, CXC | 1 | 2006 | 22 | 0.060 |
Why?
|
| Chemokine CXCL10 | 1 | 2006 | 23 | 0.060 |
Why?
|
| Probability | 1 | 2007 | 355 | 0.060 |
Why?
|
| Tissue Distribution | 1 | 2006 | 290 | 0.060 |
Why?
|
| Hyperemia | 2 | 2019 | 16 | 0.060 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2006 | 52 | 0.060 |
Why?
|
| Berberine | 1 | 2006 | 9 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2006 | 75 | 0.060 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2006 | 58 | 0.060 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2006 | 58 | 0.060 |
Why?
|
| Receptors, Angiotensin | 1 | 2005 | 11 | 0.060 |
Why?
|
| Ovalbumin | 2 | 2017 | 102 | 0.060 |
Why?
|
| Basilar Artery | 1 | 2005 | 39 | 0.060 |
Why?
|
| Losartan | 3 | 2011 | 29 | 0.060 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2005 | 81 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 990 | 0.060 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 123 | 0.060 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 3 | 2011 | 45 | 0.060 |
Why?
|
| Embryo Loss | 1 | 2005 | 5 | 0.060 |
Why?
|
| Haploinsufficiency | 2 | 2018 | 69 | 0.060 |
Why?
|
| Somites | 1 | 2005 | 19 | 0.060 |
Why?
|
| Soluble Guanylyl Cyclase | 1 | 2024 | 4 | 0.060 |
Why?
|
| Global Health | 1 | 2006 | 208 | 0.060 |
Why?
|
| Amino Acid Sequence | 3 | 2008 | 1993 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2006 | 276 | 0.050 |
Why?
|
| Lactams, Macrocyclic | 1 | 2004 | 15 | 0.050 |
Why?
|
| Benzoquinones | 1 | 2004 | 26 | 0.050 |
Why?
|
| Demography | 2 | 2016 | 190 | 0.050 |
Why?
|
| Neural Tube Defects | 1 | 2005 | 41 | 0.050 |
Why?
|
| Embryo, Mammalian | 1 | 2005 | 217 | 0.050 |
Why?
|
| Triiodothyronine | 1 | 2006 | 361 | 0.050 |
Why?
|
| Acute Disease | 2 | 2017 | 841 | 0.050 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2004 | 18 | 0.050 |
Why?
|
| Myocardial Ischemia | 2 | 2003 | 140 | 0.050 |
Why?
|
| Protein Kinase C | 1 | 2005 | 261 | 0.050 |
Why?
|
| Collateral Circulation | 1 | 2004 | 37 | 0.050 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 2 | 2004 | 5 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 829 | 0.050 |
Why?
|
| Tyrosine | 1 | 2004 | 131 | 0.050 |
Why?
|
| Vascular Patency | 1 | 2004 | 118 | 0.050 |
Why?
|
| Sesquiterpenes | 2 | 2006 | 13 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 1056 | 0.050 |
Why?
|
| Chicago | 2 | 2019 | 1464 | 0.050 |
Why?
|
| Recurrence | 1 | 2007 | 1191 | 0.050 |
Why?
|
| Sex Factors | 1 | 2007 | 1104 | 0.050 |
Why?
|
| Incidence | 2 | 2020 | 1702 | 0.050 |
Why?
|
| Cardiomyopathies | 2 | 2004 | 299 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 2368 | 0.050 |
Why?
|
| Cross-Over Studies | 3 | 2013 | 390 | 0.050 |
Why?
|
| Placenta | 1 | 2005 | 189 | 0.050 |
Why?
|
| Evaluation Studies as Topic | 1 | 2003 | 242 | 0.050 |
Why?
|
| Oxadiazoles | 1 | 2003 | 37 | 0.050 |
Why?
|
| Quinoxalines | 1 | 2003 | 51 | 0.050 |
Why?
|
| Young Adult | 3 | 2025 | 6938 | 0.050 |
Why?
|
| Capillaries | 1 | 2003 | 83 | 0.050 |
Why?
|
| Virulence Factors, Bordetella | 2 | 1993 | 25 | 0.050 |
Why?
|
| Antigen-Presenting Cells | 1 | 2004 | 145 | 0.050 |
Why?
|
| Pertussis Toxin | 2 | 1993 | 31 | 0.050 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2004 | 171 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 1516 | 0.050 |
Why?
|
| Vasoconstrictor Agents | 1 | 2003 | 67 | 0.050 |
Why?
|
| Fibrinolysis | 1 | 2003 | 36 | 0.050 |
Why?
|
| Molecular Structure | 1 | 2003 | 306 | 0.050 |
Why?
|
| Gene Transfer Techniques | 1 | 2003 | 154 | 0.050 |
Why?
|
| Chromatography | 1 | 2002 | 25 | 0.050 |
Why?
|
| Vasoconstriction | 1 | 2003 | 88 | 0.050 |
Why?
|
| Second Messenger Systems | 1 | 2002 | 39 | 0.050 |
Why?
|
| Calcimycin | 1 | 2002 | 32 | 0.050 |
Why?
|
| Ionophores | 1 | 2002 | 14 | 0.050 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2002 | 33 | 0.050 |
Why?
|
| Heart Septum | 1 | 2002 | 45 | 0.050 |
Why?
|
| Dichlororibofuranosylbenzimidazole | 1 | 2002 | 4 | 0.050 |
Why?
|
| Abdominal Muscles | 1 | 2002 | 23 | 0.050 |
Why?
|
| Cell Line, Tumor | 3 | 2016 | 2756 | 0.050 |
Why?
|
| I-kappa B Kinase | 2 | 1999 | 41 | 0.050 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2002 | 66 | 0.050 |
Why?
|
| Cytochrome P-450 Enzyme Inhibitors | 1 | 2002 | 9 | 0.050 |
Why?
|
| Clotrimazole | 1 | 2002 | 3 | 0.050 |
Why?
|
| Sialoglycoproteins | 1 | 2002 | 31 | 0.050 |
Why?
|
| HLA-DR alpha-Chains | 1 | 2002 | 4 | 0.050 |
Why?
|
| omega-N-Methylarginine | 1 | 2002 | 17 | 0.050 |
Why?
|
| Lipoproteins | 1 | 2003 | 137 | 0.050 |
Why?
|
| Cytoprotection | 1 | 2002 | 51 | 0.050 |
Why?
|
| Age Factors | 1 | 2007 | 1907 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 2 | 2002 | 890 | 0.050 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2002 | 34 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2002 | 29 | 0.050 |
Why?
|
| HLA-DR Antigens | 1 | 2002 | 56 | 0.050 |
Why?
|
| Potassium Chloride | 1 | 2002 | 75 | 0.050 |
Why?
|
| RNA Polymerase II | 1 | 2002 | 60 | 0.050 |
Why?
|
| Glutathione Transferase | 1 | 2002 | 115 | 0.050 |
Why?
|
| Adenoviridae | 1 | 2003 | 340 | 0.050 |
Why?
|
| Cell Membrane | 2 | 2002 | 661 | 0.050 |
Why?
|
| Myosin-Light-Chain Kinase | 2 | 2013 | 38 | 0.050 |
Why?
|
| Mice, Inbred Strains | 4 | 2005 | 279 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 2002 | 83 | 0.040 |
Why?
|
| Mental Health | 1 | 2003 | 189 | 0.040 |
Why?
|
| Coronary Thrombosis | 1 | 2001 | 15 | 0.040 |
Why?
|
| Myocardial Contraction | 1 | 2002 | 188 | 0.040 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2002 | 111 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2002 | 198 | 0.040 |
Why?
|
| Feedback | 2 | 2000 | 129 | 0.040 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2004 | 236 | 0.040 |
Why?
|
| Radiation Chimera | 2 | 2012 | 22 | 0.040 |
Why?
|
| Acetylcholine | 3 | 2007 | 158 | 0.040 |
Why?
|
| Atropine Derivatives | 1 | 2001 | 1 | 0.040 |
Why?
|
| Tight Junction Proteins | 1 | 2021 | 14 | 0.040 |
Why?
|
| Interferon-Stimulated Gene Factor 3 | 1 | 2001 | 2 | 0.040 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2001 | 17 | 0.040 |
Why?
|
| Biological Transport | 2 | 2000 | 399 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2025 | 3479 | 0.040 |
Why?
|
| Heart Rate | 1 | 2003 | 508 | 0.040 |
Why?
|
| Indomethacin | 1 | 2000 | 58 | 0.040 |
Why?
|
| Adaptation, Physiological | 1 | 2003 | 329 | 0.040 |
Why?
|
| Sterol Regulatory Element Binding Protein 2 | 1 | 2020 | 5 | 0.040 |
Why?
|
| Isoflurane | 1 | 2021 | 68 | 0.040 |
Why?
|
| Receptors, LDL | 2 | 2012 | 54 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2000 | 76 | 0.040 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2020 | 29 | 0.040 |
Why?
|
| Retinoblastoma Protein | 1 | 2000 | 68 | 0.040 |
Why?
|
| Patient Admission | 1 | 2021 | 119 | 0.040 |
Why?
|
| DNA Primers | 3 | 2011 | 528 | 0.040 |
Why?
|
| Pregnancy | 2 | 2021 | 3148 | 0.040 |
Why?
|
| Adolescent | 2 | 2025 | 9610 | 0.040 |
Why?
|
| ras GTPase-Activating Proteins | 1 | 1999 | 9 | 0.040 |
Why?
|
| Tunica Media | 1 | 1999 | 16 | 0.040 |
Why?
|
| Radioligand Assay | 2 | 2005 | 32 | 0.040 |
Why?
|
| Pulse Wave Analysis | 1 | 2019 | 9 | 0.040 |
Why?
|
| Endothelial Growth Factors | 1 | 1999 | 55 | 0.040 |
Why?
|
| Lymphokines | 1 | 1999 | 75 | 0.040 |
Why?
|
| Epithelial Cells | 2 | 2018 | 700 | 0.040 |
Why?
|
| Echocardiography | 1 | 2003 | 748 | 0.040 |
Why?
|
| Renin | 1 | 2019 | 67 | 0.040 |
Why?
|
| Metalloendopeptidases | 1 | 1999 | 44 | 0.040 |
Why?
|
| Cytoskeleton | 1 | 2000 | 198 | 0.040 |
Why?
|
| GTPase-Activating Proteins | 1 | 1999 | 68 | 0.040 |
Why?
|
| Retinal Vessels | 1 | 1999 | 51 | 0.040 |
Why?
|
| Microvessels | 1 | 2019 | 68 | 0.040 |
Why?
|
| rhoB GTP-Binding Protein | 1 | 1998 | 3 | 0.040 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 1998 | 11 | 0.040 |
Why?
|
| Adenylyl Cyclases | 1 | 1999 | 105 | 0.040 |
Why?
|
| Cytotoxins | 1 | 1998 | 17 | 0.040 |
Why?
|
| Illinois | 1 | 2020 | 520 | 0.040 |
Why?
|
| ADP Ribose Transferases | 1 | 1998 | 7 | 0.040 |
Why?
|
| Enzyme Induction | 1 | 1998 | 83 | 0.040 |
Why?
|
| X-Ray Microtomography | 1 | 2019 | 101 | 0.030 |
Why?
|
| Diterpenes | 1 | 1998 | 24 | 0.030 |
Why?
|
| Densitometry | 1 | 1997 | 23 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2019 | 657 | 0.030 |
Why?
|
| Bleomycin | 1 | 2018 | 99 | 0.030 |
Why?
|
| Transcription Factor RelA | 1 | 1997 | 39 | 0.030 |
Why?
|
| Bacterial Toxins | 1 | 1998 | 112 | 0.030 |
Why?
|
| Dogs | 2 | 2012 | 634 | 0.030 |
Why?
|
| Onium Compounds | 1 | 1997 | 4 | 0.030 |
Why?
|
| Platelet Activation | 1 | 2017 | 18 | 0.030 |
Why?
|
| Catalase | 1 | 1997 | 46 | 0.030 |
Why?
|
| Myofibroblasts | 1 | 2018 | 51 | 0.030 |
Why?
|
| Biphenyl Compounds | 1 | 1997 | 60 | 0.030 |
Why?
|
| Organizational Case Studies | 1 | 2017 | 24 | 0.030 |
Why?
|
| Cost Control | 1 | 2017 | 43 | 0.030 |
Why?
|
| Oxidoreductases | 1 | 1997 | 111 | 0.030 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2017 | 8 | 0.030 |
Why?
|
| Urban Health | 1 | 2017 | 55 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 1790 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 1998 | 1025 | 0.030 |
Why?
|
| Hypoxia, Brain | 2 | 2007 | 43 | 0.030 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type II | 1 | 2016 | 14 | 0.030 |
Why?
|
| Smad Proteins | 1 | 2016 | 42 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2017 | 173 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 454 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 178 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 917 | 0.030 |
Why?
|
| Respiratory Mucosa | 1 | 2017 | 90 | 0.030 |
Why?
|
| Ligands | 1 | 1997 | 476 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2002 | 2482 | 0.030 |
Why?
|
| Aerobiosis | 1 | 1995 | 21 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1165 | 0.030 |
Why?
|
| Nitrites | 1 | 1995 | 34 | 0.030 |
Why?
|
| Molsidomine | 1 | 1995 | 6 | 0.030 |
Why?
|
| Mitochondrial Proteins | 1 | 2016 | 128 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2015 | 75 | 0.030 |
Why?
|
| Glycolysis | 1 | 2016 | 187 | 0.030 |
Why?
|
| Vesicular Transport Proteins | 1 | 2015 | 70 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2015 | 200 | 0.030 |
Why?
|
| Laminin | 1 | 2015 | 89 | 0.030 |
Why?
|
| Metformin | 1 | 2016 | 125 | 0.030 |
Why?
|
| Mast Cells | 1 | 2015 | 96 | 0.030 |
Why?
|
| Immunoglobulin E | 1 | 2015 | 148 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2017 | 356 | 0.030 |
Why?
|
| Cisplatin | 1 | 2016 | 568 | 0.030 |
Why?
|
| Th2 Cells | 1 | 2015 | 149 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2017 | 376 | 0.030 |
Why?
|
| Allergens | 1 | 2015 | 189 | 0.030 |
Why?
|
| Transcription Factor AP-1 | 2 | 2006 | 66 | 0.020 |
Why?
|
| Collagen | 1 | 2015 | 300 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2013 | 43 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2013 | 13 | 0.020 |
Why?
|
| Penile Erection | 1 | 2013 | 21 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 300 | 0.020 |
Why?
|
| gamma Catenin | 1 | 2012 | 7 | 0.020 |
Why?
|
| Keratin-14 | 1 | 2012 | 5 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2013 | 69 | 0.020 |
Why?
|
| Desmosomes | 1 | 2012 | 11 | 0.020 |
Why?
|
| Catenins | 1 | 2012 | 11 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 464 | 0.020 |
Why?
|
| Liver X Receptors | 1 | 2012 | 15 | 0.020 |
Why?
|
| ATP Binding Cassette Transporter 1 | 1 | 2012 | 8 | 0.020 |
Why?
|
| Orphan Nuclear Receptors | 1 | 2012 | 15 | 0.020 |
Why?
|
| Cholesterol, Dietary | 1 | 2012 | 26 | 0.020 |
Why?
|
| Foam Cells | 1 | 2012 | 17 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2016 | 962 | 0.020 |
Why?
|
| Hair | 1 | 2012 | 55 | 0.020 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2012 | 70 | 0.020 |
Why?
|
| Integrases | 1 | 2012 | 66 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2013 | 335 | 0.020 |
Why?
|
| Epidermis | 1 | 2012 | 103 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2013 | 344 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 1992 | 303 | 0.020 |
Why?
|
| PPAR gamma | 1 | 2012 | 75 | 0.020 |
Why?
|
| Cytoskeletal Proteins | 1 | 2013 | 222 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2013 | 254 | 0.020 |
Why?
|
| Nifedipine | 1 | 2011 | 24 | 0.020 |
Why?
|
| Biological Assay | 1 | 1992 | 82 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2012 | 140 | 0.020 |
Why?
|
| RNA Interference | 1 | 2013 | 379 | 0.020 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2013 | 201 | 0.020 |
Why?
|
| Linear Models | 1 | 2013 | 414 | 0.020 |
Why?
|
| Radionuclide Ventriculography | 1 | 1991 | 3 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Pulsed | 1 | 2011 | 5 | 0.020 |
Why?
|
| Arterial Occlusive Diseases | 2 | 2004 | 106 | 0.020 |
Why?
|
| Dyspnea | 1 | 2012 | 86 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 876 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2011 | 36 | 0.020 |
Why?
|
| Plethysmography | 1 | 1991 | 16 | 0.020 |
Why?
|
| Gene Knock-In Techniques | 1 | 2011 | 28 | 0.020 |
Why?
|
| P-Selectin | 2 | 2002 | 14 | 0.020 |
Why?
|
| DNA Mutational Analysis | 2 | 2004 | 543 | 0.020 |
Why?
|
| Huntingtin Protein | 1 | 2011 | 12 | 0.020 |
Why?
|
| Amlodipine | 1 | 2011 | 5 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2011 | 120 | 0.020 |
Why?
|
| Blood Circulation | 1 | 2011 | 29 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2013 | 526 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 238 | 0.020 |
Why?
|
| Fingolimod Hydrochloride | 1 | 2010 | 31 | 0.020 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2010 | 38 | 0.020 |
Why?
|
| Adenine | 1 | 2011 | 90 | 0.020 |
Why?
|
| ROC Curve | 1 | 2013 | 775 | 0.020 |
Why?
|
| Muscles | 1 | 1991 | 184 | 0.020 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2010 | 29 | 0.020 |
Why?
|
| Leg | 1 | 1991 | 140 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2011 | 207 | 0.020 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2010 | 42 | 0.020 |
Why?
|
| Rabbits | 1 | 2011 | 613 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 580 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2011 | 315 | 0.020 |
Why?
|
| Cardiovascular Agents | 1 | 2010 | 59 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2014 | 580 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 1246 | 0.020 |
Why?
|
| E-Selectin | 2 | 1999 | 31 | 0.020 |
Why?
|
| Electrocardiography | 1 | 1991 | 494 | 0.020 |
Why?
|
| Neoplasms | 1 | 2004 | 3171 | 0.020 |
Why?
|
| Autoimmunity | 1 | 2010 | 189 | 0.020 |
Why?
|
| Plaque, Amyloid | 1 | 2009 | 66 | 0.020 |
Why?
|
| Receptor, Bradykinin B1 | 1 | 2008 | 2 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2010 | 435 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2718 | 0.020 |
Why?
|
| Placebos | 1 | 2008 | 206 | 0.020 |
Why?
|
| Melanoma | 1 | 2013 | 495 | 0.020 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2008 | 60 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2010 | 1102 | 0.020 |
Why?
|
| Keratinocytes | 1 | 2008 | 146 | 0.020 |
Why?
|
| Cell Separation | 1 | 2008 | 200 | 0.020 |
Why?
|
| Mice, Inbred ICR | 1 | 2007 | 75 | 0.020 |
Why?
|
| Neuroglia | 1 | 2007 | 77 | 0.020 |
Why?
|
| Lysophospholipids | 1 | 2007 | 67 | 0.020 |
Why?
|
| Forearm | 1 | 2007 | 32 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2007 | 303 | 0.020 |
Why?
|
| Stimulation, Chemical | 1 | 2006 | 55 | 0.020 |
Why?
|
| KB Cells | 1 | 2006 | 2 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2008 | 712 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 2008 | 373 | 0.010 |
Why?
|
| Diet | 1 | 2009 | 460 | 0.010 |
Why?
|
| Angiotensin II Type 2 Receptor Blockers | 1 | 2005 | 1 | 0.010 |
Why?
|
| Nitroarginine | 1 | 2005 | 16 | 0.010 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 2005 | 6 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2006 | 66 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 2005 | 69 | 0.010 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2006 | 68 | 0.010 |
Why?
|
| Lipids | 1 | 2006 | 278 | 0.010 |
Why?
|
| Imidazoles | 1 | 2005 | 138 | 0.010 |
Why?
|
| Intracranial Embolism | 1 | 2005 | 29 | 0.010 |
Why?
|
| Aorta, Thoracic | 1 | 2006 | 149 | 0.010 |
Why?
|
| Sp1 Transcription Factor | 1 | 2004 | 24 | 0.010 |
Why?
|
| Germany | 1 | 2004 | 81 | 0.010 |
Why?
|
| Arachidonic Acid | 1 | 2004 | 62 | 0.010 |
Why?
|
| Tibial Arteries | 1 | 2004 | 5 | 0.010 |
Why?
|
| Boston | 1 | 2004 | 36 | 0.010 |
Why?
|
| 3' Untranslated Regions | 1 | 2004 | 98 | 0.010 |
Why?
|
| Popliteal Artery | 1 | 2004 | 30 | 0.010 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2004 | 27 | 0.010 |
Why?
|
| Time | 1 | 2004 | 80 | 0.010 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2004 | 48 | 0.010 |
Why?
|
| Swine | 1 | 2005 | 587 | 0.010 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2004 | 30 | 0.010 |
Why?
|
| Veratrine | 1 | 2003 | 1 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2004 | 331 | 0.010 |
Why?
|
| Introns | 1 | 2004 | 298 | 0.010 |
Why?
|
| Hostility | 1 | 2003 | 25 | 0.010 |
Why?
|
| Lower Extremity | 1 | 2004 | 99 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2004 | 228 | 0.010 |
Why?
|
| Cricetinae | 1 | 2004 | 532 | 0.010 |
Why?
|
| Risk | 1 | 2004 | 657 | 0.010 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2003 | 107 | 0.010 |
Why?
|
| Exons | 1 | 2004 | 448 | 0.010 |
Why?
|
| Failure to Thrive | 1 | 2002 | 17 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2003 | 238 | 0.010 |
Why?
|
| Gene Targeting | 1 | 2002 | 74 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2002 | 275 | 0.010 |
Why?
|
| Psychometrics | 1 | 2003 | 337 | 0.010 |
Why?
|
| Motor Activity | 1 | 2004 | 323 | 0.010 |
Why?
|
| Calcinosis | 1 | 2002 | 222 | 0.010 |
Why?
|
| Blood Gas Analysis | 1 | 2001 | 38 | 0.010 |
Why?
|
| Morphogenesis | 1 | 2002 | 204 | 0.010 |
Why?
|
| Reoperation | 1 | 2004 | 703 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2004 | 891 | 0.010 |
Why?
|
| Skin | 1 | 2004 | 576 | 0.010 |
Why?
|
| Anxiety | 1 | 2003 | 338 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2004 | 1525 | 0.010 |
Why?
|
| Cytochalasin D | 1 | 2000 | 15 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2004 | 565 | 0.010 |
Why?
|
| GATA2 Transcription Factor | 1 | 2000 | 16 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2004 | 1723 | 0.010 |
Why?
|
| Cerebral Arteries | 1 | 2000 | 74 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 1999 | 55 | 0.010 |
Why?
|
| Matrix Metalloproteinases, Membrane-Associated | 1 | 1999 | 4 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1999 | 67 | 0.010 |
Why?
|
| Gelatinases | 1 | 1999 | 10 | 0.010 |
Why?
|
| Depression | 1 | 2003 | 544 | 0.010 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 1999 | 48 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1999 | 292 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2003 | 3061 | 0.010 |
Why?
|